A B S T R A C T Potent synthetic analogs of gonadotropin-releasing hormone produce parodoxical antireproductive effects when administered chronically. These compounds are minimally toxic and may exhibit no plateau of the dose-response curve even at very high doses. These considerations served as the basis for our systematic evaluation of [D-leucine6-desarginine-glycine-NH210]gonadotropin-releasing hormone (GnRH-A) proethylamide in the very high dose range (i.e., 10-fold larger amounts than previously used). In rats given the analog for 12 
INTRODUCTION
70,000 new cases of prostate cancer are diagnosed annually in the United States. 85% of these present with disseminated lesions and -75% are hormone dependent (1-3). Surgical castration effectively lowers androgen levels and produces tumor regression in these patients. Because this procedure is unacceptable to many men, several investigative groups have attempted to develop medical alternatives to castration. Accelerated death rates induced by cardiovascular and/or thromboembolic disease related to high-dose estrogen administration limited the usefulness of this form of "medical castration" (4) . Lower doses of estrogen produce tumor regression without cardiovascular complications but may be less effective than castration. Progestational agents alone are only transiently effective at reducing testosterone (5, 6) , whereas the recent introduction of antiandrogens (7) or combination of estrogen with progestins shows promise for a sustained reduction of testosterone levels lasting up to 16 mo in one study (8) .
Studies in a variety of species utilizing highly potent (superagonist) analogs of gonadotropin-releasing hormone (GnRH-A)' suggested an alternative approach to medical castration. Chronic administration of these compounds produces paradoxic atrophy of reproductive tissues.
[D-Leu6-des-Gly-NH210]-GnRH proethylamide (D-Leu6-GnRH) is a superagonist analog with 12-20 times greater luteinizing hormone (LH) and follicle-stimulating hormone (FSH) releasing activity than that of GnRH itself (9) . Studies in rats (10) (11) (12) (13) (14) (15) demonstrated inhibition of testosterone secretion, reduction of testicular LH receptors, and prostate regression with chronic administration of this compound. This ability to induce "reproductive atrophy" pharmacologically with this agent has suggested its potential usefulness in androgen-dependent neoplasia.
Prior studies in the rodent focused upon the inhibitory activities of 0.005-5 1sg of GnRH-A. Because these compounds are devoid of toxicity at very high doses, we initiated systematic studies to evaluate the effects of even higher doses of D-Leu6-GnRH ,ug daily) in rats bearing androgen-dependent prostate tumors and then extended these investigations using comparable doses on a milligram per square meter basis to men with prostatic carcinoma (16) . This report details the profound inhibition of gonadotropins and androgens observed with very high-dose GnRH-A therapy in these studies.
METHODS

Rodent studies
Groups of animals. Three groups of 25 adult male Noble rats bearing subcutaneous prostate tumor implants (17, 18) (19) and in patients by RIA as previously described (20, 21) . To enhance assay sensitivity, we also used RIA of urinary LH and FSH, which involved an extraction and 40-fold concentration of urine before quantitation using the same reagents as for the plasma RIA (22) . The rat interstitial cell testosterone (RICT) assay for LH of Dufau et al. (23) was used to measure biologically active LH in serum.
This assay has a limit of sensitivity of 0.4 mIU/ml and a bioassay/RIA potency ratio of 3.95±0.97 (SD, n = 168). Assay precision, sensitivity, normal ranges, specificity and physiologic studies using this assay have been previously published (23, 24) . A direct solid-phase assay was used to measure plasma cortisol (25) . RIA of testosterone and DHT used plasma extraction, LH-20 column chromatography, and then specific RIA (26) . Measurement of androstenedione involved ether extraction of 1-3 ml of plasma, celite chromatography, and then RIA by methods used extensively in prior studies (27) . Plasma progesterone and 17a-hydroxyprogesterone were assayed after extraction and column chromatography on LH-20 using specific antisera.
With the amounts of plasma extracted, the working sensitivities of the steroid RIA used included testosterone, 10 ng/100 ml; DHT, 10 ng/100 ml; progesterone, 0.1 ng/ml; and 17a-hydroxyprogesterone, 0.1 ng/ml. (Table I) . As a consequence, paired t tests were used to evaluate the statistical significance of the degree of suppressibility of various hormone levels when compared with basal values. Since the number of patients evaluated at each time point varied, unpaired t tests were used in a similar fashion for the human data. Since the experimental design required multiple comparisons between basal and treatment values, we used the Bonferroni method of analyzing multiple comparisons (28) . With this highly conservative technique, the usual P value necessary for statistical significance is divided by the number of comparisons made and thus one arrives at a lower and more stringent P value. Thus, for the rodent studies P < 0.05 is divided by the three comparisons made (i.e., basal vs. 3, 6, and 12 wk), which equals a required P value of <0.017 for statistical significance. In addition, where appropriate, analysis of variance was undertaken to evaluate overall differences between initial values and those between 2 and 11 wk in patients treated with the D-Leu6-GnRH. When hormone levels were undetectable in various assays, results were expressed as the lower limit of detectability for statistical purposes.
RESULTS
Rodent studies
LH. The administration of very high dose D-Leu6-GnRH (40 and 200 yg daily) caused an initial increase in plasma LHI concentrations at 3 wk followed by later suppression at 6 and 12 wk (Table I) . 40 ,ug daily of D-Leu6-GnRH increased LH from 33±3.8 (SEM) to 230±18 ng/ml (P < 0.01) at 2 wk, whereas 200 Mig exerted a less pronounced stimulatory effect (basal, 71±9.5 ng/ml; 3 wk, 98±6.5 ng/ml [P < 0.01]). During gg daily. In the castrate animals, a sevenfold rise in LH from 77±18 basally to 460±60 ng/ml at 12 wk was observed.
Testosterone. The levels of this steroid increased slightly but not significantly at 3 wk and then fell in response to both high doses of D-Leu6-GnRH at 6-12 wk (Table I) . At the highest dose (i.e., 200 ,ug daily), D-Leu6-GnRH suppressed testosterone to 15±2.4 and 19±2.0 ng/100 ml (P < 0.001 and P < 0.01, respectively) at 6 and 12 wk. By comparison, castration reduced testosterone to 11±1.7 and 8.8±1.0 ng/100 ml (P < 0.001 and P < 0.001) at the same time points. At the 12th wk, testosterone levels were notably significantly higher in the GnRH-A-treated animals (P < 0.02 for 40 Mg; P < 0.001 for 200 ,ug) than after castration. The levels observed after drug or castration were an order of magnitude lower than the testosterone concentrations before treatment, which ranged from 90±12 to 100±25 ng/100 ml.
Prl. All animals exhibited similar Prl levels basally and during the 12 wk of observation (Table I) . However, prolactin transiently increased during the third and sixth weeks of drug administration (Table I) .
Organ weights. Measurement of androgen target organ weights provides a bioassay of the effects of highdose GnRH-A administration. In animals receiving the 40 jg daily D-Leu6-GnRH dose prostate weight was 0.26±0.08 (SD) g and in those given 200 yg daily, 0.16±0.09 g (Fig. 1 ). This reflected a significant doseresponse effect (P < 0.01, 40 vs. 200 Mg daily). In comparison, castration reduced the weight of this organ (0.08±0.05 g) to a greater extent than either the 40 ,gg (P < 0.01) or the 200 gg (P < 0.005) doses of D-Leu6-GnRH. Dose-response effects were also noted in the seminal vesicles and testis as well (Fig. 1 ).
Human studies Dose-response data. Based on the rat data, we chose to initiate clinical studies with comparable amounts of D-Leu6-GnRH (i.e., 1,000 and 10,000 Mg) on a milligrams per square meter basis (16) . In contrast to findings in the rat, no dose-response differences were observed in the level of any hormone between patients receiving 1,000 or 10,000 ug D-Leu6-GnRH daily. For example, Fig. 2 illustrates testosterone levels expressed as percentage of control values (to facilitate comparison) in patients receiving 1,000 and 10,000 ug/d. Both doses produced an initial rise in testosterone lasting 1 wk followed by suppression to a maximum of 6% of basal values thereafter. At no time point are the responses to either dose statistically different. Consequently, for all additional data analysis, the 1,000-and 10,000-,ug dose groups were pooled and dose-response data were omitted for other hormones.
LH and FSH levels. In both the castrate and noncastrate men, LH initially rose to peak values 8 h after the first dose. For castrate men, the increase was from 71±8.4 (SEM) mIU/ml basally, to 127±14 mIU/ml (P < 0.001), whereas the noncastrate men exhibited an increment from 28±3.5 to 97±9.9 (P < 0.001) (Fig.  3 ) mIU/ml, P < 0.001) and 2 wk for the noncastrate men (13±0.9, P < 0.001). Thereafter, the titers of this gonadotropin in both groups fell further to values that bordered assay sensitivity (i.e., 85% binding on the assay standard curve) for the remainder of the 11 wk.
FSH levels similarly rose in both castrate and intact men and peaked 8 h after the initial injection. The first significant suppression occurred at 72 h in the castrate group and 2 wk in the noncastrate group. Thereafter, both groups fell further to the levels of borderline assay detectability.
To determine accurately the degree of gonadotropin suppression, highly sensitive methods of q6antitating (Fig. 7) . In intact men, testosterone levels rose initially from 323±37 ng/100 ml to 461±51 ng/100 ml at 8 h (P = <0.01) and then fell to suppressed levels (114±26 ng/100 ml) by 2 wk. Thereafter, testosterone declined further to 19±4.4 ng/100 ml (P < 0.001) at 10-11 wk, a reduction of 94% over basal. These levels approximated those observed basally (11±0.9 ng/100 ml) in 25 castrate men before therapy. DHT concentrations paralleled those of testosterone, increasing initially from 49±4.8 ng/100 ml to 87±17 ng/100 ml at 72 h (P = 0.01), and then fell to 28±4.5 ng/100 ml (P < 0.01) at 2 wk. By 10-11 wk of treatment, the levels fell further to 15±1.7 ng/100 ml (P < 0.01), a 70% reduction over basal values. This represented a level identical to castrate values in men studied under basal conditions (15±4.1 ng/100 ml, n = 23). Steroids of mixed gonadal and adrenal origin. In a subgroup of intact men, 17a-hydroxyprogesterone, androstenedione, and progesterone were measured during D-Leu6-GnRH therapy. All steroids originate from both adrenal and testicular sources, although the testis source of 17a-hydroxyprogesterone predominates (42) . Although there was a tendency for an initial rise, no statistically significant changes occurred during the first 80 h after initial injection. At 6 wk of treatment, androstenedione decreased from 0.8±0.13 ng/ml to 0.3±0.08 ng/ml and 17-hydroxyprogesterone declined similarly. These decrements, however, did not reach statistical significance because the Bonferroni correction for multiple comparisons required sigProstate Cancer Treatment: D-Leu6-Gonadotropin-releasing Hormone Analog nificance levels of P < 0.01. Use of analysis of variance to compare basal values with those observed after 2 wk of therapy also did not reveal statistically significant differences for androstenedione and 17-hydroxyprogesterone (Fig. 8) .
Initial analysis of progesterone levels revealed that all values approached assay sensitivity. Consequently, samples from 10 men before treatment and during the second to eleventh weeks of treatment were pooled to allow large extraction volumes (i.e., 2 ml). With this method of analysis values remained <0.1 ng/ml before and during treatment. Prolactin and cortisol levels. Analysis of basal and posttreatment levels of prolactin and cortisol revealed no statistically significant differences at any time between groups (data not shown).
DISCUSSION
Potent GnRH-A produce prostatic atrophy and reduction of testosterone levels in a variety of species (38) (39) (40) (41) (43) (44) (45) . Reports of these paradoxical actions stimulated several ongoing studies of GnRH-A as potential treatment strategies for androgen-dependent prostatic carcinoma in man (46) (47) (48) . We first questioned what doses of analog should be chosen for initial studies in patients. Unpublished data in rats (research files, Abbott Laboratories) suggested that very high doses of GnRH-A (i.e., doses an order of magnitude greater than previously used) might produce greater suppression of prostatic weight than lower doses. Our rodent data (Fig. 1 ) demonstrated significantly greater suppression of prostate, seminal vesicle, and testis weight with the 200 ,ug than with the 40 ,ug daily dose of D-Leu6-GnRH. This surprising dose-response effect with very high doses supported the potential usefulness of such large amounts of GnRH-A in patients. A major margin of patient safety was predicted since no toxicity occurred with amounts >10 mg/kg per d for 32 d or lower doses administered for up to 2 y in rats. Thus, for the patient trials, we chose GnRH-A doses (i.e., 1,000-10,000 ug/d) equivalent to the amounts used in rats when corrected for square meter differences (16) . These doses are in striking contrast with the much lower amounts used chronically in three recently published preliminary studies of GnRH-A administration in prostate cancer patients (46) (47) (48) . It is pertinent, then, to consider whether LH and androgen suppression were greater in the present study than in those using lower GnRH-A doses. Our data indicate a 75-90% suppression of plasma LH and FSH to the limit of detectability of the respective RIA. By comparison, Faure et al. (48) found no inhibition and Borgmann et al. (47) a 60% reduction in three patients. LH levels were not reported in the study of Tolis et al. (46) . These data support the possibility that LH suppression may be greater in patients receiving 1,000-10,000 Mg of GnRH-A daily as reported in the present study.
Since the GnRH-A exert significant direct gonadal effects in some species, it may not be necessary to suppress LH fully to achieve castrate levels of testosterone in noncastrate men treated with GnRH-A. To examine this possibility, we also compared the published levels of testosterone in men given lower amounts of GnRH-A with those in subjects receiving 1,000-10,000 ,ug daily (Table II) . As shown in Table II , the data of Faure et al. (48) and Tolis et al. (46) suggest that lower amounts of GnRH-A than used in the current study E 0.6 (6) (10) (10) 4 and 5) and testosterone to castrate levels. However, it requires emphasis that our study has not firmly established the requirement for such large amounts of drug. The relative efficacy of very high doses and of lower amounts can only be inferred currently by comparing published data. It will now be necessary to conduct full doseresponse studies in man to determine the maximal doses required. This issue is particularly important since lower doses can be administered much more practicably by the nasal spray route. Since only 1-4% of drug is absorbed by this method of delivery (51, 52) , administration of very high amounts intranasally is not feasible.
Based upon rodent studies, previous investigators emphasized the importance of the direct gonadal effects of GnRH-A in producing reproductive atrophy. These conclusions relied heavily on the observations that rodent testes contain GnRH receptors (53) and analog effects can be demonstrated in hypophysectomized animals (13, (54) (55) (56) . In addition, GnRH-A do not suppress basal LH levels in intact male rats during chronic treatment. With a variety of regimens (i.e., D-Leu6-GnRH, ng [57] ; D-Ala6-GnRH; 100 ng-1 yg [10, 58, 59 ]; D-Tryp6-GnRH, 0.001-1 ,g [12] ; Bus- erelin, 0.034-34 yg, or GnRH itself, 0.034-340 ug/d [11] ), basal LH was unchanged or increased in intact animals, while suppression occurred exclusively in castrates. Only with very high dose GnRH (i.e., 200 ug q.d.; this study) has inhibition of basal LH been demonstrated during chronic treatment in intact male rats. The biological importance of this additional effect of GnRH-A is suggested by the organ weight and testosterone data in this study (Fig. 1, Table 1 inhibited receptor content in the pituitaries of intact male rats. Thus, chronic administration of very high doses of GnRH-A may be necessary to down-regulate GnRH receptors and to suppress LH during chronic administration in the intact male rat. In addition, such doses may be required to produce the profound reduction in urinary LH and plasma LH bioactivity observed in patients in this study. The data presented serve to highlight the well-recognized species differences regarding the mechanisms whereby the GnRH-A produce reproductive atrophy (10) . In the rat, GnRH-A inhibit testicular function by a predominately testicular effect with a lesser inhibition of gonadotropin secretion. In contrast, the major effect in men is to suppress LH released by the pituitary.
The rationale for treatment of prostatic carcinoma with GnRH-A is to mimic the biologic effects of surgical castration (60) . Even with very high doses of GnRH-A, testosterone levels and reproductive organ weight did not decrease to the extent produced by castration in our rodent studies (Table I, Fig. 1 ). Previous investigators have not identified this lack of complete reproductive atrophy since castrate animals were not included as controls. In our patient studies (Fig.  7) , testosterone levels did fall to the castrate range (19±4.4 ng/dl GnRH-A, 11±0.9 ng/dl castration, P = NS) but organ weights were not available for comparative analysis. In general, these data suggest that complete inhibition of the pituitary Leydig cell axis is more easily achieved in man than in the rodent.
Nonetheless, further study of the comparative biologic effects of GnRH-A vs. castration in men is necessary.
In particular, the relative efficacy of castration and GnRH-A on prostatic tumor growth in patients as a biologic endpoint of androgen suppression is required.
In this regard, the prostate cancer response data in patients from this trial have now been published and support our contention that very high dose GnRH-A treatment mimics the clinical effects of surgical castration (61, 62) . In (40) , rams (39) , and monkeys (38, 41) is not seen in man.
Findings of low toxicity with dramatic hormonal and clinical results using very high doses of GnRH-A make it incumbent upon other investigators to explore this upper end of the dose-response range in other treatment settings. Currently, the antireproductive properties of GnRH-A are being used for precocious puberty (64, 65) , contraception (66) , gonadal sparing during chemotherapy (67) , nongonadal tumors (49, 68) , endometriosis (69) , combination hormonal therapy (70) , hirsuitism, and acne as well as other nontumorous conditions (71) .
